ClinicalTrials.gov
public full text
Public Domain
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
alzheimer-diseasecognitive-impairmentdementiadigital-phenotypingmental-disordermild-cognitive-impairmentneurocognitive-disordersneurodegenerative-diseases
This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults#883872
- Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)#852370
- Validation of NAD+ Measurements for Human Clinical Studies#881895
- N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease#1171698
- Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers#867777
Record · ID 865875
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive